APA (7th ed.) Citation

CM, K., PC, S., DY, C., & HH, C. (2026). Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study. Therapeutic advances in musculoskeletal disease, 18, 1759720X261423830. https://doi.org/10.1177/1759720X261423830

Chicago Style (17th ed.) Citation

CM, Kao, Shih PC, Chen DY, and Chen HH. "Malignancy Risk in Patients with Rheumatoid Arthritis Initiating Biological or Targeted Synthetic Disease-modifying Antirheumatic Drugs: A 5-year Population-based Cohort Study." Therapeutic Advances in Musculoskeletal Disease 18 (2026): 1759720X261423830. https://doi.org/10.1177/1759720X261423830.

MLA (9th ed.) Citation

CM, Kao, et al. "Malignancy Risk in Patients with Rheumatoid Arthritis Initiating Biological or Targeted Synthetic Disease-modifying Antirheumatic Drugs: A 5-year Population-based Cohort Study." Therapeutic Advances in Musculoskeletal Disease, vol. 18, 2026, p. 1759720X261423830, https://doi.org/10.1177/1759720X261423830.